Next Article in Journal
Classical and Alternative Activation of Rat Microglia Treated with Ultrapure Porphyromonas gingivalis Lipopolysaccharide In Vitro
Previous Article in Journal
Aflatoxin Reduction in Maize by Industrial-Scale Cleaning Solutions
Previous Article in Special Issue
Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins
Open AccessReview

FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia

Movement Disorders and Neuromodulation Center, Department of Neurology, University of California, San Francisco, CA 94115, USA
*
Author to whom correspondence should be addressed.
Toxins 2020, 12(5), 332; https://doi.org/10.3390/toxins12050332
Received: 20 March 2020 / Revised: 1 May 2020 / Accepted: 13 May 2020 / Published: 17 May 2020
(This article belongs to the Special Issue Treatment of Dystonia with Botulinum Toxins)
In 2016, the American Academy of Neurology (AAN) published practice guidelines for botulinum toxin (BoNT) in the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. This article, focusing on dystonia, provides context for these guidelines through literature review. Studies that led to Food and Drug Administration (FDA) approval of each toxin for dystonia indications are reviewed, in addition to several studies highlighted by the AAN guidelines. The AAN guidelines for the use of BoNT in dystonia are compared with those of the European Federation of the Neurological Societies (EFNS), and common off-label uses for BoNT in dystonia are discussed. Toxins not currently FDA-approved for the treatment of dystonia are additionally reviewed. In the future, additional toxins may become FDA-approved for the treatment of dystonia given expanding research in this area. View Full-Text
Keywords: botulinum toxin; dystonia; cervical dystonia; blepharospasm; FDA botulinum toxin; dystonia; cervical dystonia; blepharospasm; FDA
MDPI and ACS Style

Spiegel, L.L.; Ostrem, J.L.; Bledsoe, I.O. FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia. Toxins 2020, 12, 332.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop